Krankheitskosten sowie gesundheitsbezogene Lebensqualität (hrQoL) bei ambulant erworbener Pneumonie (CAP) – ein systematisches Review

 

 Permissions and Reprints

Zusammenfassung

Zielsetzung: Für Deutschland liegen lediglich begrenzt Daten zu den Kosten und zur gesundheitsbezogenen Lebensqualität (hrQoL) der ambulant erworbenen Pneumonie (CAP) vor. Diese Arbeit untersucht, ob sich aus der internationalen Literatur umfassendere Erkenntnisse über die Krankheitskosten der CAP und die hrQoL bei CAP generieren lassen.

Methodik: Es wurde eine systematische Literaturrecherche in elektronischen Datenbanken durchgeführt. Die Selektion der Treffer erfolgte anhand der bibliografischen Angaben. Die eingeschlossene Literatur wurde getrennt nach Krankheitskosten- bzw. hrQoL-Analysen ausgewertet.

Ergebnisse: Die Recherche ergab 172 Treffer, davon wurden 16 Publikationen zu Krankheitskosten der CAP und 5 Publikationen zu hrQoL bei CAP eingeschlossen. Lediglich zwei Publikationen sind aktuelleren Datums.

Schlussfolgerung: Es zeigt sich, dass nur wenige und veraltete Daten über die Krankheitskosten der CAP vorliegen und sich aufgrund des Studiendesigns die Studienergebnisse nicht auf Deutschland übertragen lassen. Zur Lebensqualität liegen keine verwertbaren Erkenntnisse vor, weswegen gefolgert werden kann, dass in diesem Bereich noch erheblicher Forschungsbedarf vorliegt.

Abstract

Aim: There are only very limited data available on the costs and health-related quality of life (hrQoL) of patients with community-acquired pneumonia (CAP) in Germany. The aim of this review was to identify studies in the international literature regarding the costs and hrQoL of CAP.

Method: In March 2010, a systematic literature search was performed. The acquired literature was evaluated separately for costs of illness and/or hrQoL analyses followed by a structured discussion of the findings.

Results: A total of 172 references was identified. Sixteen publications on the cost of illness for CAP and five publications on hrQoL met the selection criteria and were included in the present review.

Conclusion: There are only very limited and, furthermore, outdated data available on the costs and quality of life impacts of CAP. Hence, further research is urgently needed to fill this lack of evidence.

Literatur

• 1 Höffken G, Lorenz J, Kern W et al. Epidemiologie, Diagnostik, antimikrobielle Therapie und Management von erwachsenen Patienten mit ambulant erworbenen unteren Atemwegsinfektionen sowie ambulant erworbener Pneumonie – Update 2009.  Pneumologie. 2009;  63 e1-e68
  Article in Thieme ConnectPubMedGoogle Scholar
• 2 CAPNETZ .CAP Definition und Epidemiologie. http://www.capnetz.de/html/practitioners/cap/definition Stand: 3. Januar 2011
  Google Scholar
• 3 Bartolome M, Almirall J, Morera J et al. A population-based study of the costs of care for community-acquired pneumonia.  Eur Respir J. 2004;  23 610-616
  CrossrefPubMedGoogle Scholar
• 4 Bauer T T, Welte T, Ernen C et al. Cost analyses of community-acquired pneumonia from the hospital perspective.  Chest. 2005;  128 2238-2246
  CrossrefPubMedGoogle Scholar
• 5 Birnbaum H G, Morley M, Greenberg P E et al. Economic burden of pneumonia in an employed population.  Arch Intern Med. 2001;  161 2725-2731
  CrossrefPubMedGoogle Scholar
• 6 Colice G L, Morley M A, Asche C et al. Treatment costs of community-acquired pneumonia in an employed population.  Chest. 2004;  125 2140-2145
  CrossrefPubMedGoogle Scholar
• 7 Estrada C A, Unterborn J N, Price J et al. Judging the effectiveness of clinical pathways for pneumonia: the role of risk adjustment.  Effective Clinical Practice. 2000;  3 221-228
  PubMedGoogle Scholar
• 8 Frei C R, Burgess D. Community-acquired pneumonia: Objective criteria to predict severe disease.  J Infect Dis Pharmacother. 2004;  6 39-48
  CrossrefPubMedGoogle Scholar
• 9 Guest J F, Morris A. Community-acquired pneumonia: the annual cost to the National Health Service in the UK.  Eur Respir J. 1997;  10 1530-1534
  CrossrefPubMedGoogle Scholar
• 10 Henderson A, Cleary M, Galbraith G et al. Prospective study of costs and outcome in a major adult Australian intensive care unit utilising the APACHE III severity scoring and prediction tool.  Clinical Intensive Care. 1997;  8 58-62
  CrossrefPubMedGoogle Scholar
• 11 Kaplan V, Angus D C, Griffin M F et al. Hospitalized community-acquired pneumonia in the elderly: age- and sex-related patterns of care and outcome in the United States.  Am J Respir Crit Care Med. 2002;  165 766-772
  CrossrefPubMedGoogle Scholar
• 12 Kruse R L, Boles K E, Mehr D R et al. The cost of treating pneumonia in the nursing home setting.  J Am Med Dir Assoc. 2003;  4 81-89
  CrossrefPubMedGoogle Scholar
• 13 Lave J R, Fine M J, Sankey S S et al. Hospitalized pneumonia: Outcomes, treatment patterns, and costs in urban and rural areas.  Journal of General Internal Medicine. 1996;  11 415-421
  CrossrefPubMedGoogle Scholar
• 14 Niederman M S, McCombs J S, Unger A N et al. The cost of treating community-acquired pneumonia.  Clin Ther. 1998;  20 820-837
  CrossrefPubMedGoogle Scholar
• 15 Orrick J J, Segal R, Johns T E et al. Resource use and cost of care for patients hospitalised with community acquired pneumonia: Impact of adherence to Infectious Diseases Society of America guidelines.  PharmacoEconomics. 2004;  22 751-757
  CrossrefPubMedGoogle Scholar
• 16 Paladino J A, Adelman M H, Schentag J J et al. Direct costs in patients hospitalised with community-acquired pneumonia after non-response to outpatient treatment with macrolide antibacterials in the US.  PharmacoEconomics. 2007;  25 677-683
  CrossrefPubMedGoogle Scholar
• 17 Scott G, Scott H, Turley M et al. Economic cost of community-acquired pneumonia in New Zealand adults.  New Zealand Medical Journal. 2004;  117 (1196) U933
  PubMedGoogle Scholar
• 18 Sun H K, Nicolau D P, Kuti J L. Resource utilization of adults admitted to a large urban hospital with community-acquired pneumonia caused by Streptococcus pneumoniae.  Chest. 2006;  130 807-814
  CrossrefPubMedGoogle Scholar
• 19 Feagan B G. A controlled trial of a critical pathway for treating community-acquired pneumonia: the CAPITAL study. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin.  Pharmacotherapy. 2001;  21 (7 Pt 2) 89S-94S
  CrossrefPubMedGoogle Scholar
• 20 Palmer C S, Zhan C, Elixhauser A et al. Economic assessment of the community-acquired pneumonia intervention trial employing levofloxacin.  Clinical Therapeutics. 2000;  22 250-264
  CrossrefPubMedGoogle Scholar
• 21 Marrie T J, Lau C Y, Wheeler S L et al. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin.  JAMA. 2000;  283 749-755
  CrossrefPubMedGoogle Scholar
• 22 Carratala J F-S. Outpatient care compared with hospitalization for community-acquired pneumonia: A randomized trial in low-risk patients.  Annals of Internal Medicine. 2005;  142 165-172
  PubMedGoogle Scholar
• 23 Fine M J, Auble T E, Yealy D M et al. A prediction rule to identify low-risk patients with community-acquired pneumonia.  N Engl J Med. 1997;  336 243-250
  CrossrefPubMedGoogle Scholar
• 24 Ware J E, Kosinsky M, Keller S D. SF-36 Physical and Mental Health Summary Scales: A User’s Manual.. Boston: Health Assessment Laboratory, New England Medical Center; 1994
  Google Scholar
• 25 el Moussaoui R, Opmeer B C, de Borgie C A et al. Long-term symptom recovery and health-related quality of life in patients with mild-to-moderate-severe community-acquired pneumonia.  Chest. 2006;  130 1165-1172
  CrossrefPubMedGoogle Scholar
• 26 el Moussaoui R, Opmeer B C, Bossuyt P M et al. Development and validation of a short questionnaire in community acquired pneumonia.  Thorax. 2004;  59 591-595
  CrossrefPubMedGoogle Scholar
• 27 Gleason P P, Kapoor W N, Stone R A et al. Medical outcomes and antimicrobial costs with the use of the American Thoracic Society Guidelines for outpatients with community-acquired pneumonia.  Journal of the American Medical Association. 1997;  278 32-39
  CrossrefPubMedGoogle Scholar
• 28 Torres A, Muir J F, Corris P et al. Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia.  European Respiratory Journal. 2003;  21 135-143
  CrossrefPubMedGoogle Scholar

Dipl.-Ök. Christian Jacob

herescon gmbh
health economics research & consulting

Königworther Str. 2
30167 Hannover

Email: jacob@herescon.com